Profile data is unavailable for this security.
About the company
Absci Corporation is a generative artificial intelligence (AI) drug creation company. The Company combines AI with scalable wet lab technologies to create biologics for patients. It has built an Integrated Drug Creation platform to identify novel drug targets, discover biotherapeutic candidates, and generate the cell lines to manufacture them in a single process. The Company uses its platform to predict, identify, design, construct, screen, select and scale production of biologic drug candidates for its partners, and learn from the data it generates. Its SoluPro technology is a multiplex synthetic biology approach that overcomes the limitations of highest-throughput automation labs. The Company supports its generative AI designs with its wet lab's high-throughput functional validation capabilities. It reconstructs prevalent immune-response molecules, such as antibodies from disease tissue and identify their corresponding antigens, offering new therapeutic targets.
- Revenue in USD (TTM)5.72m
- Net income in USD-110.57m
- Incorporated2020
- Employees155.00
- LocationAbsci Corp18105 Se Mill Plain BlvdVANCOUVER 98683United StatesUSA
- Phone+1 (360) 949-1041
- Fax+1 (302) 655-5049
- Websitehttps://www.absci.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
SIGA Technologies Inc | 157.02m | 79.26m | 530.57m | 45.00 | 6.81 | 3.22 | 6.64 | 3.38 | 1.10 | 1.10 | 2.20 | 2.32 | 0.7354 | 0.3631 | 10.32 | 3,489,424.00 | 37.12 | 22.34 | 47.49 | 27.56 | 87.71 | 88.65 | 50.48 | 41.14 | 2.19 | -- | 0.00 | 29.51 | 26.31 | -21.75 | 100.76 | -30.57 | -26.67 | -- |
Astria Therapeutics Inc | 0.00 | -81.63m | 534.30m | 59.00 | -- | 1.96 | -- | -- | -2.32 | -2.32 | 0.00 | 6.70 | 0.00 | -- | -- | 0.00 | -27.34 | -64.48 | -28.18 | -68.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.62 | -- | -- | -- |
Compass Pathways PLC (ADR) | 0.00 | -129.44m | 537.17m | 186.00 | -- | 2.07 | -- | -- | -2.37 | -2.37 | 0.00 | 3.79 | 0.00 | -- | -- | 0.00 | -53.68 | -40.85 | -57.32 | -44.48 | -- | -- | -- | -- | -- | -43.34 | 0.1009 | -- | -- | -- | -29.46 | -- | -12.68 | -- |
Y-mAbs Therapeutics Inc | 84.50m | -21.67m | 538.76m | 100.00 | -- | 5.43 | -- | 6.38 | -0.496 | -0.496 | 1.93 | 2.26 | 0.6481 | 1.31 | 4.30 | 844,990.00 | -16.62 | -44.23 | -19.95 | -50.45 | 86.53 | -- | -25.64 | -181.13 | 5.67 | -- | 0.00 | -- | 29.96 | -- | 77.58 | -- | -- | -- |
GeneDx Holdings Corp | 221.85m | -135.02m | 542.63m | 1.00k | -- | 2.62 | -- | 2.45 | -5.25 | -5.25 | 8.60 | 7.93 | 0.4721 | 9.16 | 7.27 | 221,849.00 | -28.73 | -- | -35.07 | -- | 50.57 | 11.50 | -60.86 | -121.10 | 2.99 | -130.27 | 0.2015 | -- | -13.69 | 8.72 | 67.98 | -- | 7.77 | -- |
Arbutus Biopharma Corp | 12.99m | -74.39m | 543.51m | 73.00 | -- | 4.53 | -- | 41.85 | -0.4393 | -0.4393 | 0.0766 | 0.6362 | 0.0761 | -- | 5.41 | 177,890.40 | -43.56 | -52.62 | -50.25 | -58.11 | -- | -- | -572.81 | -537.81 | -- | -- | 0.00 | -- | -53.51 | 25.00 | -4.89 | -- | -2.40 | -- |
PetIQ Inc | 1.10bn | 2.13m | 547.94m | 1.93k | 300.47 | 2.45 | 11.16 | 0.4972 | 0.0614 | 0.0614 | 35.69 | 7.52 | 1.31 | 5.63 | 8.46 | 570,079.10 | 0.301 | -4.32 | 0.3777 | -5.23 | 22.94 | 20.05 | 0.2304 | -3.66 | 1.43 | 1.74 | 0.6671 | -- | 19.58 | 15.83 | 104.42 | -- | 4.96 | -- |
OmniAB Inc | 34.16m | -50.62m | 548.24m | 106.00 | -- | 1.74 | -- | 16.05 | -0.4986 | -0.4986 | 0.3292 | 2.69 | 0.0858 | -- | 2.00 | 322,301.90 | -12.71 | -- | -13.55 | -- | -- | -- | -148.16 | -- | -- | -- | 0.00 | -- | -42.17 | -- | -126.65 | -- | -- | -- |
Avid Bioservices Inc | 136.74m | -17.96m | 550.37m | 365.00 | -- | 3.05 | -- | 4.03 | -0.284 | -0.284 | 2.17 | 2.84 | 0.302 | 3.18 | 4.89 | 374,616.40 | -3.97 | 10.73 | -6.03 | 15.22 | 7.47 | 22.72 | -13.13 | 25.92 | 0.3097 | -5.04 | 0.4548 | 0.00 | 24.81 | 22.72 | -99.56 | -- | 82.90 | -- |
IGM Biosciences Inc | 2.11m | -236.92m | 550.62m | 216.00 | -- | 3.41 | -- | 261.58 | -4.31 | -4.31 | 0.0375 | 2.74 | 0.005 | -- | -- | 9,397.32 | -56.49 | -44.66 | -62.57 | -48.20 | -- | -- | -11,255.25 | -23,668.96 | -- | -- | 0.00 | -- | 99.25 | -- | -11.45 | -- | 73.48 | -- |
Absci Corp | 5.72m | -110.57m | 555.24m | 155.00 | -- | 2.59 | -- | 97.10 | -1.20 | -1.20 | 0.0621 | 1.89 | 0.0212 | -- | 3.06 | 36,890.32 | -41.08 | -- | -46.22 | -- | -- | -- | -1,933.65 | -- | -- | -93.25 | 0.0467 | -- | -0.5046 | -- | -5.40 | -- | -- | -- |
Phathom Pharmaceuticals Inc | 682.00k | -201.59m | 557.44m | 452.00 | -- | -- | -- | 817.36 | -3.89 | -3.89 | 0.0133 | -1.26 | 0.0024 | -- | -- | 1,508.85 | -69.68 | -83.26 | -78.50 | -93.77 | 75.51 | -- | -29,558.94 | -135,982.00 | 10.22 | -4.91 | 1.20 | -- | -- | -- | -1.96 | -- | -- | -- |
Humacyte Inc | 0.00 | -110.78m | 559.70m | 183.00 | -- | 35.97 | -- | -- | -1.07 | -1.07 | 0.00 | 0.1307 | 0.00 | -- | -- | 0.00 | -66.63 | -- | -75.23 | -- | -- | -- | -- | -- | -- | -88.38 | 0.5819 | -- | -100.00 | -- | -825.83 | -- | -- | -- |
Aerovate Therapeutics Inc | 0.00 | -75.52m | 569.86m | 51.00 | -- | 5.03 | -- | -- | -2.87 | -2.87 | 0.00 | 3.94 | 0.00 | -- | -- | 0.00 | -57.49 | -- | -63.65 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -46.61 | -- | -- | -- |
Exscientia PLC (ADR) | 25.14m | -182.76m | 581.41m | 483.00 | -- | 1.30 | -- | 23.13 | -1.45 | -1.45 | 0.20 | 3.54 | 0.0346 | 1,096.08 | 9.86 | 52,051.47 | -25.16 | -- | -29.09 | -- | -36.47 | -- | -726.94 | -- | 6.22 | -- | 0.0505 | -- | -26.24 | -- | -22.94 | -- | -- | -- |
Northwest Biotherapeutics Inc | 1.93m | -64.37m | 583.33m | 25.00 | -- | -- | -- | 301.93 | -0.0573 | -0.0573 | 0.0017 | -0.04 | 0.0653 | -- | -- | 77,280.00 | -211.53 | -381.58 | -- | -- | -- | -- | -3,240.11 | -6,479.25 | -- | -- | -- | -- | 14.80 | 36.21 | 38.71 | -- | 77.88 | -- |
Holder | Shares | % Held |
---|---|---|
Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 13.86m | 12.29% |
Redmile Group LLCas of 01 Mar 2024 | 8.25m | 7.32% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 3.42m | 3.04% |
ARK Investment Management LLCas of 31 Mar 2024 | 3.28m | 2.91% |
Casdin Capital LLCas of 31 Dec 2023 | 973.26k | 0.86% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 886.66k | 0.79% |
Platinum Investment Management Ltd.as of 31 Dec 2023 | 837.60k | 0.74% |
Geode Capital Management LLCas of 31 Dec 2023 | 662.68k | 0.59% |
Millennium Management LLCas of 31 Dec 2023 | 527.74k | 0.47% |
Susquehanna Financial Group LLLPas of 31 Mar 2024 | 493.64k | 0.44% |